CD81 as target for B cell lymphomas

In this issue of JEM, Vences-Catalán et al. (https://doi.org/10.1084/jem.20190186) demonstrate that a particular anti-CD81 antibody shows promising features as a novel immunotherapeutic tool to treat B cell lymphomas. Surprisingly, although CD81 is widely expressed, only minor side effects on other CD81+ immune cells analyzed were observed.
Source: The Journal of Experimental Medicine - Category: Internal Medicine Authors: Tags: Leukemia & Lymphoma Insights Source Type: research